The function of G protein-coupled receptors (GPCRs) can be modulated by compounds that bind to other sites than the endogenous orthosteric binding site, so-called allosteric sites.
"pre-crystal structure" research. 19 It is also the most conserved residue of the sodium ion site amongst GPCRs. The high conservation of the sodium ion pocket amongst class A GPCRs makes it probable that more structures with sodium ions bound in this site will emerge. There is little if any conservation present in the other GPCR classes, which makes it improbable that such a sodium ion binding site exists in these GPCRs.
Amiloride is primarily known as a potassium-sparing diuretic drug, acting through the blockade of renal epithelial sodium channels. 20 Amiloride and its analogs have also been found to bind to the sodium ion site of several GPCRs, modulating orthosteric ligand binding. 21 The negatively charged carboxylate of sodium ion site residue Asp 2.50 supposedly interacts with the positively charged guanidinium group present in all amilorides. The binding of amilorides into the sodium ion site of class A GPCRs renders these compounds potential pharmacological tools to probe molecular mechanisms of GPCR allosteric modulation. The chemical structures of amiloride and its analogs discussed in this review are depicted in Figures 1,2 . Effects of the amilorides are represented in Table 1 categorized per GPCR and orthosteric ligands used. Most of the receptors in Table 1 are discussed in the main text.
| ADENOSINE RECEPTORS
Adenosine receptors have been studied extensively, and as a result, many orthosteric 22 and allosteric 23 ligands have been discovered. Amiloride interactions with adenosine receptors were discovered in the early days of adenosine F I G U R E 1 Chemical structures of amiloride and its 5′-amino substituted analogs DMA, EIA, MIBA, MBA, HMA, and MGCMA. DMA, 5-(N,N-dimethyl)amiloride; EIA, 5-(N-ethyl-N-isopropyl)amiloride; HMA, 5-(N,Nhexamethylene)amiloride; MBA, 5-(N-methyl-N-butyl)amiloride; MGCMA, 5-(N-methyl-N-guanidinocarbonylmethyl)amiloride; MIBA, 5-(N-methyl-N-isobutyl)amiloride receptor research. 24 Since the effects of amiloride binding to adenosine receptors appeared to be closely tied to sodium ion interactions, it was necessary to investigate and exclude the involvement of Na + /H + exchange proteins (one of the main targets of amiloride) in these interactions. 21 In this study, Garritsen et al 21 
found inhibition of antagonist [ 3 H]
DPCPX and agonist [ 3 H]PIA at the calf adenosine A 1 receptor by amiloride, its 5′-amino-substituted analogs 5-(N,N-hexamethylene)amiloride (HMA), 5-(N-methyl-N-butyl)amiloride (MBA), 5-(N-methyl-N-guanidinocarbonyl-methyl) amiloride (MCGMA), and 5-(N-methyl-N-isobutyl)amiloride (MIBA), and its 2-guanidino substituted analogs benzamil, 5-(N-4-chlorobenzyl)-2′,4′-dimethylbenzamil (CBDMB), 3′,4′-dichlorobenzamil (DCB), and phenamil. Gao and IJzerman 25 found that amiloride analogs benzamil, HMA, MCGMA, MIBA, and phenamil increased the dissociation rate of the antagonist [ 3 H]ZM-241,385 at the rat A 2A receptor, and that they were more potent than amiloride itself ( Figure 3 ). However, the affinity (defined by radioligand displacement in equilibrium) and the allosteric potency (defined by the concentration-dependent effect on the radioligand dissociation rate) did not correlate. This indicated a mixed competitive (ie, mutually exclusive displacement) and noncompetitive behavior of amilorides, in which amilorides and orthosteric ligands bind to the receptor at the same time, whereas amiloride influences the orthosteric ligand's dissociation rate. The amiloride analogs HMA and MIBA, with a lipophilic moiety on the 5′-position, proved to be the most potent compounds in increasing the dissociation rate of the orthosteric ligand, whereas they had equal affinities to benzamil and phenamil in displacing it. In contrast to the effect of amilorides, sodium ions decreased the dissociation rate of [ 3 H]ZM-241,385. Still, sodium ions and HMA appeared to compete for the same allosteric site.
In a study by Gao et al 26 it appeared that adenosine receptor agonizts and antagonists are differently affected by amilorides. Amilorides increased the dissociation rates of antagonists [ 3 Amilorides decreased the dissociation rate of agonist [ 125 I]-AB-MECA at the rat adenosine A 3 receptor, revealing that amilorides can also act as positive allosteric modulators depending on the radiolabeled probe used. 26 Furthermore the amilorides exhibited selectivity for the different adenosine receptor subtypes. Amiloride and 5-(N,N-dimethyl)amiloride (DMA) were more potent at the A 1 receptor in accelerating antagonist dissociation, whereas HMA was the most potent at the A 2A receptor and to a lesser extent at the A 3 receptor.
Solving the crystal structure of the adenosine A 2A receptor at a resolution of 1.8 Å provided a sufficiently high resolution to detect a sodium ion bound in its allosteric binding site for the first time ( Figure 4A ). 13 The amino acids interacting with the sodium ion in this site are highly conserved amongst other GPCRs which confirmed previous studies in which modulation by sodium ions was tied to the same amino acids for different GPCRs. 12 The most conserved amino acid is a negatively charged aspartic acid (Asp52 2.50 ) which interacts directly with the positively charged sodium ion by means of a salt bridge. In molecular dynamics simulations, Gutiérrez-de-Terán et al 27 observed that the interaction of the sodium ion with Asp52 2.50 is highly stable in the receptor's inactive conformation. The presence of the ion also avoids rotamer changes in two other highly conserved residues, Trp246 6.48 and Asn280 7.45 . Interestingly, an active receptor conformation caused the site to contract to expel the sodium ion from this allosteric binding site. These calculations agree very well with radioligand binding studies on A 2A AR ( Figure 5A ). 13, 27, 28 Sodium ions induced an increase in [ 3 H]ZM-241,385 antagonist binding, but inhibited [ 3 H]NECA agonist binding in a concentration dependent-manner ( Figure 5A ), 27 suggesting among others that the binding of agonist and sodium ions can be considered as "mutually exclusive". 29 Interestingly, the IC 50 value of NaCl to inhibit agonist binding was approximately 50 mM, suggesting that under physiological conditions ([NaCl] = 140 mM) the receptor is predominantly in an inactive state.
The positively charged guanidinium moiety of amiloride and its analog HMA may also interact with Asp52 2.50 in a manner similar to sodium ions, as inferred from docking studies ( Figure 4B ). Radioligand binding studies with antagonist [ 3 H]ZM-241 385 and agonist [ 3 H]NECA demonstrated amiloride and more strongly so HMA to reduce radioligand binding, with greater potency on agonist binding for both ( Figure 5B and 5C). 27 In a subsequent study, Massink et al 30 introduced amino acid mutations in the sodium ion binding site to assess the key residues in the interaction between amiloride/HMA and A 2A AR. 30 Mutation of the polar residues in the ZM-241,385 binding. Conversely, a big potency gain was observed on the W246A 6.48 mutant. HMA's IC 50 value increased 25-fold from 8.9 to 0.36 µM; a similar gain was observed for amiloride, from 63 to 2.6 µM. Apparently, this tryptophan residue, part of a so-called activation micro-switch, 31 hinders amilorides to bind in hA 2A R (and possibly other GPCRs). Indeed, at the adenosine A 3 receptor, the mutation of Trp243 6.48 into Ala increased the affinity of HMA as well. 32 These findings fueled the ambition to design and synthesize novel amiloride/HMA derivatives. The Derivative 12l also showed an increased potency compared to that of HMA for the W246A 6.48 mutant receptor, 19-fold compared to WT for HMA in this study and 76-fold for 12l. 33 The conformational flexibility of the adenosine A 2A receptor was examined further in a 19 F NMR study, providing evidence for the occurrence of four different states of activation. Interestingly, both HMA and a partial agonist favored the population of an active state (S 3 ), still different from the S 3′ active state induced by full agonists. 34 In a later study by the same team, the effects of NaCl were analyzed, leading to the conclusion that sodium ions reinforce an inactive ensemble of states (S 1-2 ), as well as the partial-agonist, stabilized state (S 3 ). HMA competed with the sodium ions, reflected in its effects on both line broadening and chemical shift perturbations in the 23 Na NMR binding isotherm. 35 F I G U R E 4 A, The Na + -distorted octahedral coordination in the A 2A AR crystal structure (PDB: 4EIY): the first shell is occupied by two conserved polar residues (green) and three water molecules (small spheres), which contact with the second shell of residues (cyan), or with a second layer of water molecules connecting with a third shell of residues (magenta). B, Docking of HMA in the sodium ion binding site. The guanidinium group of HMA has a salt bridge interaction with Asp52 2.50 whereas the 5′-azepane moiety of HMA clashes with Trp246 6.48 . ZM-241,385 is the orthosteric antagonist. Reproduced with permission from Gutiérrez-de Terán et al 27 
| 697
In conclusion, the effects of amiloride and derivatives have been most extensively studied on adenosine A 2A receptors, through a number of orthogonal approaches. They all hint in the same direction, that is the amilorides compete with sodium ions at the allosteric sodium ion binding site in which Asp 2.50 is the central amino acid. The evidence for other GPCRs is less exhaustive but suggests similar conclusions, which will be discussed below.
| ADRENERGIC RECEPTORS
One of the first indications that amiloride inhibited the binding of orthosteric ligands at αand β-adrenergic receptors were found in 1987 by Howard et al, 36 which was followed by many studies with amiloride and its analogs at a number of adrenergic receptor subtypes. At the human α 1A -adrenergic receptor amiloride and its analogs benzamil, DMA, 5-(N-ethyl-N-isopropyl)-amiloride (EIA), MIBA, and HMA increased the dissociation rate of antagonist [ 3 H]prazosin, and the analogs with bulky lipophilic 5′-moieties were more potent in doing so. 37, 38 Amiloride itself was characterized as an allosteric modulator acting at one allosteric site, but all the amiloride analogs appeared to bind to two different allosteric sites. The authors speculated that these allosteric sites could be present on one receptor or on a receptor dimer, but could not further confirm this. 37 The allosteric interaction by amilorides was seemingly in contradiction with previous results at rat and mouse α 1 -adrenergic receptors in which amiloride only showed a competitive interaction with antagonist [ 3 H]prazosin binding but did not influence its dissociation rate. 36 yohimbine. 40 Amiloride analogs also increased antagonist dissociation from the α 2A -adrenergic receptor, which was found for (N-2-aminoethyl-N-isopropyl)amiloride-N-(4-azidosalicylamide; A-EIA-AS) at the porcine receptor, 41 42 It is noteworthy that A-EIA-AS has no affinity for the Na + /H + exchange protein, making it a GPCR selective amiloride. EIA, HMA, and MIBA were exceptionally strong negative allosteric modulators of antagonist binding, being 50-to 80-fold more potent than amiloride in increasing the dissociation rate of [ 3 H] yohimbine, showing that bulky lipophilic moieties at the 5′-position of amiloride increase the allosteric potency at the α 2A -adrenergic receptor considerably. The apparent affinities of these amilorides were not correlating at all with their derived allosteric potencies in this study, cautioning to not confuse these two different pharmacological properties with each other.
In contrast to their effect on antagonists, amiloride, DMA, and HMA decreased the dissociation rate of agonist GTPγS binding experiments. This paradoxical behavior was in line with previous findings that amilorides displace the orthosteric ligand competitively from the α 2A receptor in addition to their allosteric effects. 42 Moreover, the addition of sodium ions increased the affinity of amiloride in doing so. 36 This led to the conclusion that at α 2Aadrenergic receptors amilorides bind to two different sites, namely the orthosteric site and an allosteric sodium ion site. Howard et al 36 hypothesized that amiloride binding in the orthosteric site was enhanced by binding of a sodium ion in the allosteric site, whereas amiloride binding in the allosteric site increased the dissociation rate of other orthosteric ligands. In a later study by Leppik et al, 42 observed variations in the affinity of several amiloride analogs for the antagonist-occupied and unoccupied receptor led to two different hypotheses. Either the amilorides bind to both the allosteric and orthosteric sites, or binding of an antagonist to the orthosteric site modified the conformation of the allosteric binding site in such a way that amiloride's affinity decreased. 42 At the α 2B subtype, however, amilorides both increased and decreased the dissociation rate of antagonists. The 5′-substituted amilorides EIA and MIBA increased the dissociation rate of [ 3 H]rauwolscine binding, whereas the guanidino-substituted amiloride CBDMB decreased it. 44 The interaction of amiloride with β-adrenergic receptors has only been studied by Howard et al in 1987. At both the β 1and β 2 -adrenergic receptors amiloride displaced the antagonist [ 125 I]iodocyanopindolol competitively, because their binding was mutually exclusive. 36 Addition of sodium ions did not compete with amiloride binding, and it was concluded that amiloride did bind to the orthosteric site rather than to an allosteric sodium ion site.
Despite the lack of modulation of β-adrenergic receptors by sodium ions and amiloride, a sodium ion site was found in the crystal structure of the β 1 -adrenergic receptor. 14 The amino acids forming the sodium ion sites of the β 1adrenergic and the adenosine A 2A receptor are the most similar of the solved GPCR crystal structures with such a site. 12 That makes the difference in modulation by sodium ions and amilorides between these receptors remarkable and it is probably due to differences in the overall architecture of the two receptors.
| CHEMOKINE RECEPTORS
Amiloride interactions with the chemokine receptor family have only been studied by Zweemer et al 45 on the chemokine CCR2 receptor. The sodium ion site was the third binding site found on this receptor, next to the more extracellularly located orthosteric and an intracellular allosteric site. [46] [47] [48] [49] binding to the intracellular site. 45 Moreover, HMA inhibited binding of the orthosteric agonist [ 125 I]CCL2.
Amiloride, benzamil, MCGMA, and phenamil did however not displace any of these radioligands. The allosteric effect of HMA was diminished by mutation of sodium ion site residues Asp88 2.50 and His297 7.45 into Ala. Mutation of Trp256 6.48 even completely abolished HMA's allosteric effect, which is in contrast to the observed increase of HMA's affinity by the same mutation in adenosine receptors as discussed above. 32 Amino acid His297 7.45 is different from most class A GPCRs which usually harbor an Asn at the same position, but is conserved amongst chemokine receptors. The binding of HMA in CCR2s sodium ion binding site indicates that amiloride binding allows for a certain variation in the amino acids that constitute this binding cavity.
| DOPAMINE RECEPTORS
The general trend amongst the dopamine receptor subtypes is an increase of the dissociation rate of orthosteric ligands by amiloride and its analogs, as found in a comprehensive study of the effect of amiloride, benzamil, and MIBA. 50 dopamine receptors, and of these amilorides HMA was the most potent amiloride (Figure 7) . Agonists were modulated similarly as antagonists by amilorides at the rat D 2 and D 3 dopamine receptors, because amiloride, DMA, and MIBA decreased the potency of the agonist dopamine in inducing receptor activation in functional assays. 50, 54 At the D 4 receptor the allosteric effect of amiloride and its analogs was too small to be measured accurately, but an increase in antagonist [ 3 H]spiperone dissociation rate was still detected. As amilorides still inhibited binding of the orthosteric ligand the displacement was more competitive in nature. 50 The amino acids forming the sodium ion site in the dopamine receptors are conserved as well. Computational and mutagenesis studies at the D 2 receptor have confirmed the importance of Asp80 2.50 , Ser121 3.39 , Asn419 7.45 , and Asn423 7.49 for the allosteric effects by sodium ions. [55] [56] [57] At the D 4 dopamine receptor mutation of Asp80 2.50 into Asn decreased MIBA affinity, 58 indicating that amilorides bind in the sodium ion binding site as well. It may be assumed that amilorides also bind in the sodium ion binding site of the other dopamine receptors, but this has not been confirmed yet.
| GONADOTROPIN-RELEASING HORMONE RECEPTOR
The gonadotropin-releasing hormone (GnRH) receptor, also known as luteinizing hormone-releasing hormone receptor, is targeted by various drugs in the market for the treatment of sex-hormone-dependent diseases such as breast or prostate cancer. 59, 60 These drugs are mostly peptidic agonists and antagonists that need to be administered by subcutaneous or intramuscular injections. The development of small-molecule ligands that may replace these peptidic ligands is therefore desirable. 61 Earlier results had indicated allosteric modulation of GnRH-stimulated luteinizing hormone release by sodium ions and amilorides. 62 In that light, the allosteric effects of amilorides on the GnRH receptor were investigated by Heitman et al 63 and M 3 receptors. 21 In rat trachea amiloride inhibited muscarinic M 3 receptor-mediated smooth muscle contraction 64 by the endogenous agonist acetylcholine, by an insurmountable noncompetitive interaction as its efficacy (E max ) was reduced. 65 In rat parotic acini, which express the muscarinic M 3 receptor, 66 amiloride inhibited binding of the muscarinic receptor antagonist [ 3 H]N-methylscopolamine in a competitive manner. 67 In the recent, relatively low-resolution crystal structures of the muscarinic M 2 and M 3 receptors sodium ion binding was not detected, [68] [69] [70] but the amino acids making up the sodium ion site are perfectly conserved when compared to adenosine and adrenergic receptors, 12 making amiloride binding to this site likely. In a recent molecular dynamics study sodium ion binding to (deprotonated), Asp 2.50 in the muscarinic M 3 receptor was suggested, keeping the receptor in an inactive state. 71 Along a similar vein, the egress pathway of a sodium ion from Asp 2.50 in the muscarinic M 2 receptor into the cytosol was also simulated in molecular dynamics calculations. 72 
| SEROTONIN RECEPTORS
Amiloride and analogs have been found to inhibit orthosteric ligand binding to serotonin receptors. Benzamil inhibited agonist [ 3 H]8-OH-DPAT binding at the rat 5-HT 1A receptor. 21 Amiloride and EIA inhibited agonist [ 3 H]5carboxamidotryptamine binding at the human 5-HT 1B receptor. 73 In functional assays at the same receptor, amiloride inhibited receptor activation by agonist sumatriptan in a competitive manner, whereas EIA displayed partial agonistic activity as it inhibited forskolin-stimulated cAMP formation, albeit with a 15-fold higher EC 50 value (200 µM) compared to its K i in inhibiting [ 3 H]5-carboxamidotryptamine binding (13 µM). 73 Endogenous agonist [ 3 H] serotonin binding was inhibited by HMA at the rat 5-HT 1C receptor and by benzamil and HMA at the rat 5-HT 2 receptor. 21 Crystal structures of the agonist bound 5-HT 1B receptor 74 1.96 Å resolution. 76 This high-resolution structure enabled the authors to inspect the putative sodium ion binding site around Asp100 2.50 , better than in an earlier crystal structure of this receptor. 77 Interestingly, and somewhat at odds with this review, the authors identified two water molecules rather than a sodium ion in the vicinity of this aspartic acid residue.
Triggered by this absence they performed additional radioligand binding studies in which no effects were observed from the addition of sodium ions or amiloride derivatives, whereas such effects were found in a control experiment the authors performed on the hA 2A R.
The receptors discussed above all belong to the class A family of GPCRs. Finally, we should like to discuss the evidence, admittedly limited and inconclusive, of amiloride interaction with two class C receptors.
| GABA B RECEPTORS
The GABA B receptor is activated by γ-aminobutyric acid (GABA) and it's derivative, baclofen (β-4-chlorophenyl-GABA). This receptor is coupled to potassium and calcium channels through G i /G o proteins. 78 Ong and Kerr explored the interaction of amiloride and its analogs with baclofen-induced depression of spontaneous discharges in rat isolated neocortical slices in Mg 2+ -free medium. The effect of baclofen (10 µM) was blocked by amiloride (200 µM), which increased the frequency of discharges and slightly reduced their amplitude when applied alone.
These effects persisted upon wash-out and baclofen remained ineffective on the discharges until 30 to 60 minutes after a switch to amiloride-free medium. Analogs of amiloride, DMA and MIBA, showed a similar mode of action, whereas they were at least twice as potent than amiloride in preventing the effect of baclofen on neocortical spontaneous discharges. DMA alone increased the discharge frequency and slightly reduced the amplitude in a concentration of 100 µM. Analogs lacking the guanidine moiety were ineffective. The authors explicitly stated, however, that an indirect effect of the amilorides via functional antagonism of coactivated adenosine A 1 receptors cannot be ruled out. 79 
| T1R2/T1R3 RECEPTORS
The heterodimeric T1R2 and T1R3 taste receptor acts as a sweet taste sensor with multiple binding sites for sweeteners. 80 Amiloride (3 mM) were found to significantly reduce the responses to sweeteners such as sugar, artificial sweeteners, and sweet protein. Moreover, response inhibition of 1 mM aspartame by amiloride was observed in a concentration-dependent manner with an IC 50 value of 0.87 ± 0.20 mM. A study of the specificity towards the response mediated by the human sweet taste receptors showed that the suppression of receptor activity by amiloride is specific for hT1R2/hT1R3. Inhibitory effects of lactisole, a known hT1R2/hT1R3 inhibitor, and amiloride on the cellular response to aspartame were examined in cells expressing hT1R3 mutants (hT1R2/ hT1R3-A733V and hT1R2/hT1R3-F778A). Lactisole was less active on the mutants, whereas amiloride did not show such a differential effect. These results suggest that the binding site of amiloride is distinct from that of lactisole. 81 Amiloride inhibited the response of perillartine as a sweet activator on hT1R2/T1R3, T1R2, and T1R2heptahelical domain (HD). Molecular modeling suggested that perillartine and amiloride occupy the same binding pocket on the extracellular side of the hT1R2-HD. 82 
| FUTURE DIRECTIONS FOR DRUG DISCOVERY
It is increasingly realized that GPCRs have multiple binding sites that may influence each other in allosteric ways.
The surge in crystal structures over the last decade has taught that ligands, including marketed drugs and clinical candidates, may have very different binding sites indeed. From this review, it has become obvious that the sodium ion binding site is yet another receptor domain to tune the ligand response, and that amiloride and its derivatives are prototypic small molecules that intervene with that site.
Does this offer options for future drug discovery? One might argue that the generic nature of the site and the evolutionary conservation of the amino acids aligning it are a drawback rather than an opportunity. In that view amilorides are another class of chemical probes that serve to unveil the complexities of GPCR functioning. A recent development, however, may prove this hypothesis wrong.
The crystal structure of the leukotriene B 4 (LTB 4 ) receptor BLT1 in complex with antagonist/inverse agonist BIIL260 has recently been reported. 83 Chemically, BIIL260 has four phenyl rings, three of which are bound in the orthosteric binding site near the extracellular domain. The fourth (a protonated benzamidine moiety) is penetrating deeper into the transmembrane domain and interacts with Asp66 2.50 , with which it forms a salt bridge. Hydrogen bonds are present with the hydroxyl groups of Ser106 3.39 and Ser276 7.45 ( Figure 8A ). Mutation of Asp 2.50 or Ser 7.45 to alanine markedly reduced the affinity of BIIL260 for the receptor providing also pharmacological evidence for the BIIL260's binding to the sodium ion binding site. Furthermore, benzamidine itself, as well as NaCl, served as negative allosteric modulators of radiolabeled agonist ([ 3 H]LTB 4 ) binding ( Figure 8B ), suggesting their capability of forcing the receptor in an inactive state. 83 The chemical resemblance of amiloride's guanidine moiety and benzamidine might be a good starting point to further study the effects of amiloride and its analogs on the BLT1 receptor.
| CONCLUDING REMARKS
This review summarizes the current knowledge of the allosteric effects of amiloride and its analogs on GPCRs.
Allosteric effects of amilorides have been found on class A GPCRs (adenosine receptors, α-adrenergic receptors, the CCR2 chemokine receptor, dopaminergic receptors, the gonadotropin-releasing hormone receptor, the histamine H 1 receptor, muscarinic receptors, opioid receptors, and serotonin receptors), and, less convincingly, on class C receptors (GABA B and T1R2/3 receptors).
Amiloride and its analogs seem to follow a few general "rules" in their activity on these receptors. The propensity of amilorides to bind to the well-conserved sodium ion site amongst GPCRs may explain these common behaviors. For most receptors, amiloride analogs with bulky lipophilic moieties on the 5′-position have greater affinity and potency than the unsubstituted parent compound. This has not been explained fully, but it is clear that in most GPCRs there is a hydrophobic pocket above the sodium ion site that can accommodate these lipophilic moieties. Most receptors allow substitution on the guanidinium group as well, with a good affinity in displacing orthosteric ligands, but with less or no (allosteric) effect on the dissociation of orthosteric ligands.
Another general "rule" is the importance of Asp 2.50 for amiloride binding, just as for sodium ions. In the docking studies performed, the binding mode of amiloride and HMA was predicted in the sodium ion site of the adenosine A 2A receptor crystal structure and a CCR2 chemokine receptor homology model. The positively charged guanidinium group has a strong salt bridge interaction with Asp 2.50 , underlining the great importance of this residue for amiloride binding as found before in mutagenesis studies. Trp 6.48 interacts with amilorides as well, in some cases hampering and in other cases accommodating amiloride binding. These interactions of amilorides with the amino acids of the sodium ion site are of interest because these have been shown to be important in receptor functionality, with Asp 2.50 and Trp 6.48 as most noticeable examples. Mutation of Asp 2.50 silences receptor activation in many GPCRs. 84 Trp 6.48 is noteworthy as part of an "activation micro-switch" between the active and inactive states of GPCRs, 31, 85 and in docking studies of the adenosine A 2A receptor amiloride and HMA seem to toggle this amino acid from one rotamer to another. Although not very likely, amilorides may also influence the oligomerization of class A receptors. The interface for receptor dimerization often involves transmembrane domains 4 and 5 that are not part of the sodium ion binding site. In some cases, however, other domains such as TM6, which also flanks the sodium ion binding site, play a role. 86 In contrast with these general "rules," differences in the affinities, potencies, and modulatory behaviors of amilorides can be quite outspoken, even between receptors where the sodium ion site harbors the same amino acids (i.e. adenosine, adrenergic, dopamine, and muscarinic receptors). To appreciate these differences it is important to discern between the different properties by which the allosteric effect of amilorides on orthosteric ligand binding may be described. In Table 1 we collected values for the different amilorides, of their affinity in displacing orthosteric ligands (IC 50 or K i ), their (allosteric) effect on the dissociation of orthosteric ligand (k off /k off (control) ), and their potency for these dissociation effects (EC 50 ). This information also helps to understand whether the interaction of a particular amiloride with an orthosteric ligand is competitive or noncompetitive. If amiloride inhibits orthosteric ligand binding but does not affect its dissociation rate, the binding is mutually exclusive and the interaction is defined as competitive. If the dissociation rate is changed though, both the orthosteric ligand and amiloride can bind to the receptor at the same time and the interaction is deemed noncompetitive. Another way to confirm a noncompetitive interaction is by showing insurmountability of the inhibiting effect in radioligand saturation (B max decrease) or functional assays (E max decrease), as discussed for the chemokine CCR2, muscarinic M 3 , and gonadotropin-releasing hormone receptor. However, these assays have been conducted far less than dissociation assays in amiloride research so we did not include these in Table 1 .
In some cases, amilorides behave only as purely competitive inhibitors, whereas in other cases they behave as noncompetitive negative modulators, and a mixed behavior has also been observed. For some receptors the cause for mixed competitive/noncompetitive behavior was explained by a tendency of amilorides to bind both orthosteric and allosteric sites, but also in these cases the observed effect may be caused by binding in the sodium ion site only, where the competitive "fraction" of the allosteric effect is caused by either an overlap of binding with the orthosteric site or a conformational change of the receptor by amiloride binding. The latter option is quite likely from the structural evidence provided by the recently elucidated crystal structures.
At some of the discussed receptors, the modulatory effect by amilorides is probe-dependent, which has been described in other cases of allosteric modulation as well. 87, 88 Amilorides act as positive allosteric modulators for agonist binding and as negative modulators for antagonists at the α 2A -adrenergic and adenosine A 3 receptors. Thus, in some cases, amilorides may also influence receptor signaling after agonist activation with consequences for effector bias or functional selectivity, for instance between G protein and β-arrestin signaling. 89, 90 This has, however, not been demonstrated yet. At the α 2B -adrenergic receptor different amilorides even exhibit both positive and negative modulatory effects on the same orthosteric probe. Some of the differences in affinity and modulatory effect may be caused by differences in the sodium ion site itself, but the substantial conservation of the sodium ion site residues amongst GPCRs makes it more likely that these differences are caused by variations in receptor conformations.
Clinical application of amilorides targeting GPCRs is not self-evident due to their micromolar affinities and lack of selectivity. However, it may be feasible to synthesize amiloride analogs with variations on the 5′-position to improve their affinity and selectivity for GPCRs. In that sense, the recent structure elucidation of the BLT1/ leukotriene B 4 receptor in complex with BILL260 ( Figure 8 ) is noteworthy. BIIL260 is a selective, high-affinity antagonist for this receptor, occupying both the sodium ion and the orthosteric binding site. With the ongoing expansion of the crystal structure pool of GPCRs, further study and knowledge of the mechanisms of amiloride modulation will help in understanding and appreciating the allosteric mechanism in GPCR functioning and may pave the way for the design of antagonists forcing the receptor in a deeply inactive state.
